Bendamustine, Bortezomib And Dexamethasone (Bvd) In Patients With Relapsed-Refractory Multiple Myeloma (Mm): Updated Results Of A Multicenter Phase Ii Study

Introduction: Bendamustine, a bifunctional alkylating agent, exerts a mechanism of action different from that of other conventional alkylators despite it remains mostly unknown. In patients with newly diagnosed or relapsed-refractory MM bendamustine has proven to be active either as monotherapy or in combination with new drugs, particularly bortezomib and immunomodulatory agents.